Elusys releases data on anthrax anti-toxin

Elusys Therapeutics, Inc., released data on Wednesday regarding three recent studies of its anthrax anti-toxin ETI-204.

The studies were done by injecting ETI-204 by intramuscular injection into cynomolgus monkeys.

The first study was randomized, blinded, seven-arm, placebo-controlled, post-challenge and used a timed-treatment. The monkeys were exposed to anthrax spores and then treated after 18, 24 or 36 hours with a single dose of ETI-204. The results showed that the animals with the injections of ETI-204 had much higher survival rates than those that were only given placebos, with 100 percent surviving in the 18 hour group, 83 percent in the 24 hour group and 50 percent in the 36 hour group.

In the second study, the monkeys were exposed to anthrax and given a single dose of ETI-204 24, 36 or 48 hours after exposure. The group receiving the injection after 24 hours showed survival rates of 93 percent, with the other two groups coming in at 43 percent and 29 percent, respectively.

A third study looked at ETI-204's ability to protect before being exposed to anthrax. The monkeys were given the shot 24, 48 or 72 hours before exposure. All animals given the shot before exposure survived.

"These three recent studies demonstrate promising results of ETI-204 when given to anthrax exposed animals via intramuscular administration," Elizabeth Posillico, president and CEO of Elusys, said. "ETI-204 could offer an important complement to the current anthrax countermeasures."